Dr Michael Portman Illuminates the Differences Between Pediatric, Adult Anticoagulation Studies
Pharmaceutical companies would have to spend a lot of money on pediatric anticoagulation studies for diseases that are rare among these patients, explained Michael A. Portman, MD, FAHA, of Seattle Children's Hospital.
Pharmaceutical companies would have to spend a lot of money on pediatric
Transcript
Why have there been few studies on the use of pediatric anticoagulation?
I think it’s most due to the interest [from] the pharmaceutical companies and spending the money. They would have to spend a lot of money on relatively few patients who would take their medications. So for
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Promising Early Efgartigimod Response Data for Generalized Myasthenia Gravis
September 18th 2025
- Iron Dysregulation Linked to MS Progression, Review Finds
September 18th 2025
- Metabolic Issues More Common in Patients With HIV
September 18th 2025
- Barriers to Gender-Affirming Surgery Persist Despite High Satisfaction Rate
September 18th 2025